Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC
19. November 2024 07:07 ET
|
Panavance Therapeutics Inc.
New finding builds upon previous confirmation of misetionamide’s direct inhibition of NFkB Direct targeting of these two transcription factors inhibits multiple downstream signaling pathways in...